Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Research and Development Expenses and Reimbursements Due

Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three and six months ended June 30, 2016 and 2015, is presented as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Research and development expense, gross	$	6,827	$	3,820	$	11,789	$	7,801
Less: Reimbursement of research and development expense	168		538		387		732
Research and development expense, net of reimbursements	$	6,659	$	3,282	$	11,402	$	7,069

Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

	June 30,
	2016	2015
Warrants to purchase Series C-1 Preferred	14,033	14,033
Warrants to purchase common stock	4,218,750	—
Stock options	1,804,473	1,153,369